GlucoTrack Inc. has announced promising results from its first-in-human trial of its implantable continuous blood glucose monitoring (CBGM) system. The findings, which were presented at the American Diabetes Association's 85th Scientific Sessions, highlight the safety and performance of the device, which measures glucose directly from the blood without the need for on-body wearables. This innovative approach, capable of lasting up to three years, aims to redefine diabetes management by offering real-time, accurate readings and minimizing daily disruptions for patients. GlucoTrack's technology is currently limited to investigational use as it progresses toward the next phase of clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.